Leading Growth Driver in the Cancer Immunotherapy Drug Discovery Outsourcing Market in 2025: High R&D Costs Fueling Growth in Cancer Immunotherapy Drug Discovery Outsourcing Market Driver's Influence

What combination of drivers is leading to accelerated growth in the cancer immunotherapy drug discovery outsourcing market?
The anticipated surge in cancer immunotherapy drug discovery outsourcing market is attributable to the steep costs associated with research and development. This escalation in prices stems from the necessity for specialized skills, high-priced apparatus, and the innate risks associated with groundbreaking concepts. By offloading drug discovery tasks, economies of scale from contractual research organizations (CROs) are leveraged. This can aid small-scale biotech firms and startups in refining their research & development budgets and the distribution of resources, thus boosting cost-efficiency. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the pharmaceutical industry, reported that the total pharmaceutical R&D expenditure in Europe was around $49,500 million (€44,500 million) in 2022, marking an approximate increase of 6.45% from $46,500 million (€42,533 million) in 2021. Consequently, the steep cost of internal research and development is fueling the expansion of the cancer immunotherapy drug discovery outsourcing market.

Get Your Cancer Immunotherapy Drug Discovery Outsourcing Market Report Here:
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-drug-discovery-outsourcing-global-market-report

What is the projected compound annual growth rate (CAGR) of the cancer immunotherapy drug discovery outsourcing market from 2025 to 2034, and what factors influence it?
Rapid expansion has been observed in recent years in the market for outsourcing cancer immunotherapy drug discovery. The market, valued at $1.5 billion in 2024, is projected to climb to $1.68 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.6%. This surge during the historical period can be accredited to a rise in adverse drug reaction cases, a heightened requirement for widespread genomic testing, an escalating global prevalence of cancer, an increased demand for focused treatment, and an up-tick in clinical trials.

In the coming years, the market size of outsourcing for cancer immunotherapy drug discovery is anticipated to exhibit rapid expansion. It is projected to reach $2.57 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.3%. Factors contributing to growth during the forecast period include heightened emphasis on personalized medicine, growth in diagnostic tests, a surge in personalized cancer therapy, amplified healthcare spending, and an increase in cancer incidence and awareness. The forecast period also foresees major trends like progress in diagnostic technologies, advancements in next-generation sequencing (NGS), the application of artificial intelligence (AI), the growth of liquid biopsy technologies, the emergence of point-of-care companion diagnostic devices, and innovative testing technologies.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15528&type=smp

How are the latest trends influencing the growth of the cancer immunotherapy drug discovery outsourcing market?
In order to aid in the manufacturing of cancer treatments and generate competitiveness in the market, key firms in the cancer immunotherapy drug discovery outsourcing domain are embracing a strategic partnership strategy. This usually entails two or more businesses, merging their expertise, resources, and efforts towards shared objectives. For instance, in February 2022, Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical enterprise, collaborated with Bristol-Myers Squibb, a US biopharmaceutical entity. They formed an outsourcing agreement with Prime Research Institute for Medical Research, Inc., a Japan-based research institute to conduct a comprehensive clinical investigation centered on gastric cancer sufferers undergoing therapy with Opdivo (nivolumab) combined with chemotherapy. The project, supported by the industry, incorporates a large-scale, multi-institutional study that applies PRiME-R's CyberOncology system for managing and integrating practical data in regular cancer clinical procedures. The study, which harnesses CyberOncology, evaluates the use of Opdivo coupled with chemotherapy for advanced or recurrent gastric cancer that has not been previously treated. Approximately 30 medical establishments across the country are involved in this endeavor, which seeks to optimize data input, improve data precision, and hasten analysis.

What are the major segments of the cancer immunotherapy drug discovery outsourcing market and their role in driving growth?
The cancer immunotherapy drug discovery outsourcing market covered in this report is segmented -

1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies And Cancer Vaccines, Other Drug Types
2) By Service Type: Target Identification And Validation, Lead Screening And Characterization, Cell-Based Assays
3) By Therapeutic Area: Lung Cancer, Breast Cancer, Melanoma, Other Therapeutic Areas

Subsegments:
1) By Monoclonal Antibodies: Checkpoint Inhibitors, Therapeutic Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
2) By Immunomodulators: Cytokines, Immune Checkpoint Modulators, Toll-Like Receptor Agonists, Immune Adjuvants
3) By Oncolytic Viral Therapies And Cancer Vaccines: Oncolytic Virus-Based Therapies, Cancer Vaccines, Viral Vectors For Immunotherapy
4) By Other Drug Types: Adoptive Cell Therapy, Immune Cell Modulators, Small Molecule Immune Modulators, Gene Editing And Immunotherapy

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15528

North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the cancer immunotherapy drug discovery outsourcing market?
Major companies operating in the cancer immunotherapy drug discovery outsourcing market are Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, WuXi AppTec Co Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Evotec SE, Shanghai ChemPartner Co. Ltd., Aragen Life Sciences Limited, GenScript Biotech Corporation, BGI Genomics Co. Ltd., NeoGenomics Laboratories Inc., ARUP Laboratories, Syngene International Limited, BioDuro-Sundia, Ambry Genetics Corporation, Selvita, Crown Bioscience International, CENTOGENE N.V., Jubilant Biosys, Oncodesign Services, Icagen Inc., Reaction Biology Corporation, ChemBridge Corporation

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=15528&type=smp

What Is Covered In The Cancer Immunotherapy Drug Discovery Outsourcing Global Market Report?

•Market Size Forecast: Examine the cancer immunotherapy drug discovery outsourcing market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the cancer immunotherapy drug discovery outsourcing market for a structured understanding.
•Key Players Overview: Analyze major players in the cancer immunotherapy drug discovery outsourcing market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the cancer immunotherapy drug discovery outsourcing market.
•Segment Contributions: Evaluate how different segments drive overall growth in the cancer immunotherapy drug discovery outsourcing market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the cancer immunotherapy drug discovery outsourcing market.
•Industry Challenges: Identify potential risks and obstacles affecting the cancer immunotherapy drug discovery outsourcing market.
•Competitive Landscape: Review strategic developments in the cancer immunotherapy drug discovery outsourcing market, including expansions, agreements, and new product launches.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.